Dimethylsulfamoyl chloride

CAS No. 13360-57-1

Dimethylsulfamoyl chloride( —— )

Catalog No. M11344 CAS No. 13360-57-1

Dimethylsulfamoyl Chloride is a kind of small molecular compounds with fomula C2H6ClNO2S.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 28 In Stock
50MG 43 In Stock
100MG 56 In Stock
200MG Get Quote In Stock
500MG 128 In Stock
1G 184 In Stock

Biological Information

  • Product Name
    Dimethylsulfamoyl chloride
  • Note
    Research use only, not for human use.
  • Brief Description
    Dimethylsulfamoyl Chloride is a kind of small molecular compounds with fomula C2H6ClNO2S.
  • Description
    Dimethylsulfamoyl Chloride is a kind of small molecular compounds with fomula C2H6ClNO2S.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    13360-57-1
  • Formula Weight
    143.59
  • Molecular Formula
    C2H6ClNO2S
  • Purity
    >98% (HPLC)
  • Solubility
    Limited solubility
  • SMILES
    CN(C)S(Cl)(=O)=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Kevill DN, et al. Org Biomol Chem. 2006 Apr 21;4(8):1580-6.
molnova catalog
related products
  • 5-amino-1-[4-(triflu...

    5-amino-1-[4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile is a compound used as a molecular building block.

  • [Pro3]-GIP (Mouse)

    GIP receptor antagonist (IC50 = 2.6μM). Inhibits GIP-stimulated insulin release from pancreatic β cells in vitro. In ob/ob mice, blocks the effects of GIP on insulin release and plasma glucose levels. Also improves intraperitoneal glucose tolerance, insulin sensitivity, and glucose response to feeding in ob/ob mice.

  • SM-102

    SM-102 is an ionizable amino lipid that can be used for the formation of lipid nanoparticles (LNPs). SM-102 has the potential for development of lipid nanoparticles for delivery of mRNA-based vaccines.